2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Transplantation, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Immunodeficiency, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

6072 Efficient collection, manufacturing and timely release with demonstration of high-level fetal hemoglobin induction using a lentivirus shmir vector targeting BCL11A in the multi-center pivotal GRASP trial for sickle cell disease (SCD)

John P Manis, MD, Myriam Armant, PhD2, Helene Vincon, MEng3, Pei-Chi Kao, PHD4, Erica Esrick, MD5, Ned K. Waller, MD PhD FACP6, Mehrdad Abedi, MD7, Gary J. Schiller, MD8, Sonali Chaudhury, MD9, Neena Kapoor, MD10, Joseph Antin, MD11, Mary Horowitz, MD12, Michael A. Pulsipher, MD13, Jerome Ritz, MD14, Heather Daley15, Sarah Nikiforow, MD, PhD16, Jose A Cancelas, MD, PhD17, Carolyn Lutzko18, Donald Kohn, MD19, Sohini Roy20, Beatriz Campo-Fernandez, PhD21, Colleen Allen, MPH22, Leah Cheng, MA, CCRP23, Lauren Holmes, BS24, Boya Liu, PhD25, David Justus, MD26, Wendy London, PhD27, Mark C Walters I, MD28, Mary Eapen, MBBS29, David A. Williams, MD30
1 Boston Children's Hospital, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States
4 Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Emory University School of Medicine, Atlanta, Georgia, United States
7 University of California Davis School of Medicine, Sacremento, California, United States
8 David Geffen School of Medicine at UCLA, Los Angeles, California, United States
9 Ann & Robert H. Lurie Children's Hospital of Chicago-Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
10 Children’s Hospital Los Angeles, Los Angeles, California, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
13 Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 UCLA David Geffen School of Medicine, Los Angeles, California, United States
20 University of California, Los Angeles, Los Angeles, California, United States
21 University of California, Los Angeles, Los Angeles, California, United States
22 The EMMES Company, Rockvillee, United States
23 Boston Children's Hospital, Boston, Massachusetts, United States
24 Boston Children's Hospital, Boston, Massachusetts, United States
25 Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
26 Boston Children's Hospital, Boston, Massachusetts, United States
27 Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
28 University of California San Francisco, San Francisco, California, United States
29 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
30 Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background: Gene therapy for SCD is constrained by the difficulty of collecting and manufacturing an adequate drug product (DP). Commercially approved DP manufacture requires collecting at least 16-20×10⁶ CD34+ cells/kg, often over multiple mobilization cycles, adding delays, continued transfusion support and timelines from preparative transfusion to infusion often exceeding 1 year. We report collection, manufacturing, product-quality outcomes and associated costs for patients with SCD in the NHLBI/CIRM-funded GRASP multi-center pivotal Phase 2 trial (NCT05353647, BMTCTN 2001) who received autologous CD34+ cells transduced with a lentiviral vector encoding a short hairpin RNA embedded in a microRNA scaffold (shmiR) targeting BCL11A.

Methods: In this intent-to-treat report, cell collection and manufacturing data from all GRASP trial runs were analyzed from apheresis through release of certificate of analysis. Process metrics included number of hematopoietic stem cells (HSC) collected, CD34+ enrichment, pre-stimulation, transduction, formulation, and release testing. DP vector copy number (VCN), individual erythroid colony fetal hemoglobin (HbF) induction were assessed. Both peripheral blood HbF and F-cells with whole blood VCN at 6 months were examined to assess on-target γ-globin re-induction from the DP. Protocol specified target collection over 2 days was 10 x 106 CD34+ cells/kg and target DP of 4 x 106 CD34+ cells/kg.

Results: 26 patients at 8 centers underwent stem cell mobilization and apheresis collection. Sixteen patients (61.5%) obtained sufficient cells for manufacturing a DP during a single 2-day mobilization cycle; 9 (34.6%) required 2 cycles, and 1 (3.8%) required 3.The median total CD34+ per apheresis collection was 4.41 × 108 cells (range 1.35 × 108–13.9 × 108), corresponding to 6.55 × 106 CD34+ cells/kg (range 1.71–18.65 × 106/kg) and resulting in a median per subject total of 11.49 ×10⁶ CD34+ cells/kg, well below the required target for commercial DP. 38 GMP manufacturing runs at two academic centers were completed with a manufacturing success rate of 94.7% (36/38). The median CD34+ cell recovery after column separation was 61.1% (range 26.0–100.9%) with a median CD34+ cell purity of 94.8% (range 68.9–99.7%). The final cryopreserved DP from each mobilization cycle contained a median CD34+ dose of 4.65 (range: 0.91–12.63 × 106/kg). The protocol DP dose of 4×10⁶ cells/kg, which is higher than the 3×10⁶ cells/kg required for commercial dose, was met for all patients despite substantially lower CD34+ cell input. Transduction efficiency was 79 ±11% (mean ±SD, n=36 GMP manufacturing runs). Mean DP VCN was 4.2 ± 1.3 copies/cell (median 4.0, range 2.0-7.0; n=35), and 86% ±8% (mean ±SD, n=35) of DP-derived erythroid colonies demonstrated robust induction of >30% HbF by individual colony HPLC, well above the release criteria. Using observed manufacturing recovery, we developed a predictive model estimating collection of approximately 10.2×10⁶ CD34+ cells/kg would yield a final DP of 6.2×10⁶ CD34+/kg in 90% of patients. For the infused products, the median days from first mobilization to DP release for subjects collected in one cycle was 38 days (range 24 to 51) and for those requiring 2 cycles, median of 88 days (range 42 to 211). Biological activity of the DP was confirmed at 6 months post-infusion with median peripheral blood F-cells of 89.5% (mean 85.7%; range 48.5-96.5%, n=25 of 26 patients) and median whole-blood HbF of 43.4% (range 24.4-57.2%, n=26) consistent with DP analysis of erythroid colony induction of HbF. A cost analysis demonstrated a total direct manufacturing cost less than $125,000 per manufacturing run, exclusive of vector costs. Correlation with the trial’s primary endpoint of VOE occurrences which is being adjudicated independently will be reported after 2-years of follow-up.

Conclusion: Our platform manufactured a high-quality DP for all patients from multiple sites, mostly from a single 2-day collection using about half the CD34+ cells of commercial programs, with a favorable product VCN and robust in vitro and in vivo HbF induction, and a short time from mobilization to release. By lowering the cell-collection burden, accelerating time to product infusion, and demonstrating modest processing costs, this approach may widen the availability of potentially transformative therapy for SCD and supports the feasibility of decentralized, point-of-care academic manufacturing.

John P Manis, MD: Vertex Therapeutics - Honoraria; Terumo BCT inc - Honoraria; Gamida Cell - Consultancy (Includes expert testimony); Vertex Therapeutics - Consultancy (Includes expert testimony); Terumo BCT inc - Consultancy (Includes expert testimony)